Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Femyso is a combined oral contraceptive (COC) tablet marketed by Lupin Pharma Canada. It is a generic formulation containing norethindrone acetate (a progestin) and ethinyl estradiol (an estrogen). The primary mechanism of action is the prevention of pregnancy by suppressing the release of gonadotropins, specifically follicle-stimulating hormone (FSH) and luteinizing hormone (LH), which inhibits ovulation. Additionally, it induces changes in the cervical mucus, increasing its viscosity to impede sperm penetration, and alters the endometrial lining to reduce the likelihood of implantation. It is indicated for the prevention of conception in women who elect to use oral contraceptives.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on norethindrone acetate + ethinyl estradiol (Lupin Limited).